What is the 13F Pro Quality Score for ABVC?

13F Pro ranks ABVC BIOPHARMA, INC. (ABVC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABVC's current score at https://13fpro.ai/research/ABVC (free sign-up required for the full ranking).

Where does 13F Pro source ABVC data?

All ABVC BIOPHARMA, INC. fundamentals and ownership data come directly from SEC EDGAR. ABVC BIOPHARMA, INC. files with the SEC under CIK 1173313. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABVC in?

ABVC BIOPHARMA, INC. (ABVC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ABVC research updated on 13F Pro?

ABVC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ABVC BIOPHARMA, INC.(ABVC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1173313 ABVC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 14 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ABVC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ABVC BIOPHARMA, INC. (ABVC), a Healthcare sector company. ABVC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 14 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), ABVC BIOPHARMA, INC. reports net income of $-1.6M, free cash flow of $-894.2K. Top institutional holders of ABVC by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. ABVC trades on the Nasdaq exchange and files with the SEC under CIK 1173313. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABVC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABVC BIOPHARMA, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-1.6M

Free Cash Flow

Q1 2026

$-894.2K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+94.2% YoY

$296.0KFY 2025

FY20 $483.0KFY21 $355.8KFY23 $152.4KFY25 $296.0K

Net Income

-1.5% YoY

$-7.9MFY 2025

FY20 $-10.6MFY21 $-12.8MFY23 $-7.8MFY25 $-7.9M

Operating Income

-5.7% YoY

$-7.2MFY 2025

FY20 $-8.5MFY21 $-11.7MFY23 $-6.8MFY25 $-7.2M

EPS (Diluted)

+78.3% YoY

$-0.39FY 2025

FY20 $-0.50FY21 $-0.51FY23 $-1.80FY25 $-0.39

Total Assets

+170.6% YoY

$21.1MFY 2025

FY20 $11.6MFY21 $13.7MFY23 $7.8MFY25 $21.1M

Total Debt

-16.0% YoY

$755.5KFY 2025

FY20 $1.6MFY21 $1.6MFY23 $899.3KFY25 $755.5K

Op. Cash Flow

+28.7% YoY

$-3.0MFY 2025

FY20 $-4.6MFY21 $-7.6MFY23 $-4.2MFY25 $-3.0M

Metric	FY 2025	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$296.0K +94.2%	$152.4K -57.2%	$355.8K -26.3%	$483.0K -31.2%	$701.7K +9988.0%	$7.0K
Net Income	$-7.9M -1.5%	$-7.8M +39.3%	$-12.8M -21.2%	$-10.6M -169.3%	$-3.9M +35.1%	$-6.1M
Operating Income	$-7.2M -5.7%	$-6.8M +42.2%	$-11.7M -37.6%	$-8.5M -145.9%	$-3.5M -24.2%	$-2.8M
EPS (Diluted)	$-0.39 +78.3%	$-1.80 -252.9%	$-0.51 -2.0%	$-0.50	—	$-0.02
Total Assets	$21.1M +170.6%	$7.8M -43.2%	$13.7M +18.0%	$11.6M +67.5%	$6.9M +16.6%	$5.9M
Total Debt	$755.5K -16.0%	$899.3K -45.2%	$1.6M +0.7%	$1.6M -15.1%	$1.9M +113.3%	$899.3K
Operating Cash Flow	$-3.0M +28.7%	$-4.2M +44.9%	$-7.6M -66.5%	$-4.6M -45.6%	$-3.1M -248.1%	$-900.5K

AI Insight: ABVC Financial Trends

ABVC remains pre-revenue with deepening losses; Q1 2026 net loss of $2M and operating loss of $2M persist despite zero debt reduction.

• Revenue remains negligible: $0M across most quarters, with only $1M in Q3 2025, indicating no sustained commercial traction.

• Net losses accelerated in Q4 2025 to $4M, then moderated to $2M in Q1 2026; cumulative losses exceed $15M over trailing eight quarters.

• Operating cash burn steady at $1M per quarter; total debt stable at $1M but equity halved from $8M (Q2 2024) to $11M (Q1 2026).

⚠ Q4 2025 marked worst quarterly loss ($4M net, $3M operating); runway sustainability depends on equity fundraising or operational pivot.

⚠ Equity volatility: collapsed to $1M in Q4 2024, then recovered to $12M in Q3 2025, then declined again to $11M; indicates balance-sheet stress.

AI Insight: ABVC Ratio Trends

ABVC is persistently unprofitable with deteriorating returns; TTM ROIC of -73.9% and Q3 2025 operating margin of -172.4% signal fundamental operational distress.

• Operating margin collapsed to -172.4% in Q3 2025, paired with -184.0% net profit margin, indicating severe cash burn and operational losses.

• ROE swung wildly from +74.8% in Q4 2024 to -128.7% in Q2 2025, then -128.3% in Q4 2025, reflecting erratic and negative shareholder value creation.

• Debt-to-equity improved to 0.01 in TTM and Q1 2026 from 0.69 in Q4 2024, showing reduced leverage despite operational losses.

⚠ TTM ROA of -43.7% and ROIC of -73.9% indicate the company is destroying asset and invested capital; no sign of profitability inflection.

⚠ Q3 2025 marked the nadir across profitability metrics; subsequent quarters (Q4 2025, Q1 2026) show modest recovery in ROE/ROA but remain deeply negative.

Get alerted when ABVC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ABVC BIOPHARMA, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABVC

GEODE CAPITAL MANAGEMENT, LLC
$214.6K221,169 sh
VANGUARD CAPITAL MANAGEMENT LLC
$184.9K190,574 sh
VANGUARD FIDUCIARY TRUST CO
$94.4K97,363 sh
RENAISSANCE TECHNOLOGIES LLC
$92.3K95,100 sh
STATE STREET CORP
$70.6K72,800 sh
BlackRock, Inc.
$54.8K56,442 sh
NORTHERN TRUST CORP
$31.1K32,087 sh
TWO SIGMA SECURITIES, LLC
$20.4K21,023 sh
DIMENSIONAL FUND ADVISORS LP
$11.9K12,227 sh
JANE STREET GROUP, LLC
$10.4K10,700 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$214.6K	221,169
VANGUARD CAPITAL MANAGEMENT LLC	$184.9K	190,574
VANGUARD FIDUCIARY TRUST CO	$94.4K	97,363
RENAISSANCE TECHNOLOGIES LLC	$92.3K	95,100
STATE STREET CORP	$70.6K	72,800
BlackRock, Inc.	$54.8K	56,442
NORTHERN TRUST CORP	$31.1K	32,087
TWO SIGMA SECURITIES, LLC	$20.4K	21,023
DIMENSIONAL FUND ADVISORS LP	$11.9K	12,227
JANE STREET GROUP, LLC	$10.4K	10,700

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ABVC on your watchlist

Track score changes the day ABVC BIOPHARMA, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABVC a good stock to buy?

13F Pro's AI-powered analysis of ABVC BIOPHARMA, INC. (ABVC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABVC are available on the ABVC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ABVC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABVC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ABVC BIOPHARMA, INC.'s investment landscape.